24.79

0.41% 0.10

After Hours: 24.78 -0.010 -0.04%

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $24.79, with a volume of 705.77K. It is up +0.41% in the last 24 hours and up +9.21% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$24.69

Open:

$25.25

24h Volume:

705.77K

Relative Volume:

0.98

Market Cap:

$975.44M

Revenue:

$734.86M

Net Income/Loss:

$5.14M

P/E Ratio:

198.32

EPS:

0.125

Net Cash Flow:

$132.71M

1W Performance:

-2.44%

1M Performance:

+9.21%

6M Performance:

+13.46%

1Y Performance:

-3.95%

1-Day Range:

$24.74

$25.60

1-Week Range:

$23.47

$27.13

52-Week Range:

$18.80

$27.64

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

650-242-8052

Address

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Employee

829

Twitter

Next Earnings Date

2026-04-30

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	24.79	971.50M	734.86M	5.14M	132.71M	0.125
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

May 05, 2026

Pacira BioSciences Mails Letter to Stockholders - The Manila Times

May 05, 2026

PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill

May 05, 2026

May 04, 2026

How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm

May 04, 2026

May 03, 2026

Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily

May 03, 2026

Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data - Yahoo Finance

May 03, 2026

May 02, 2026

Pacira Biosciences Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Sales Forecast Maintained - Moomoo

May 02, 2026

Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat

May 02, 2026

Pacira BioSciences (PCRX) Return To Profitability Tests Bullish Growth Narratives - Sahm

May 02, 2026

Pacira BioSciences Reports Strong First Quarter Growth for EXPAREL - HarianBasis.co

May 02, 2026

May 01, 2026

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - The Globe and Mail

May 01, 2026

Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat

May 01, 2026

Pacira BioSciences Stock (US6951271005): Analyst Rating Change and Price Move on May 1, 2026 - AD HOC NEWS

May 01, 2026

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade - MarketBeat

May 01, 2026

RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating - marketscreener.com

May 01, 2026

Vanguard Capital Management (PCRX) reports 2.09M-share stake in Pacira - Stock Titan

May 01, 2026

Vanguard Portfolio Management (PCRX) reports 2.59M shares, 6.38% stake - Stock Titan

May 01, 2026

Pacira (PCRX) Q1 2026 Earnings Call Transcript - AOL.com

May 01, 2026

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - Yahoo Finance

May 01, 2026

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 01, 2026

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - The Motley Fool

May 01, 2026